Brian T. Powl - Chief Commercial Officer
Greg Mann - Corporate Participant
Mollie Leoni - Chief Medical Officer
Thomas Doyle - Senior Vice President of Finance & Accounting
Troy Edward Wilson - Chairman, CEO & President
Conference Call Participants
Ellen Horste - TD Cowen, Research Division
Eric Tatenda Musonza - UBS Investment Bank, Research Division
Jason Eron Zemansky - BofA Securities, Research Division
Li Wang Watsek - Cantor Fitzgerald & Co., Research Division
Peter Green - Unidentified Company
Peter Richard Lawson - Barclays Bank PLC, Research Division
Roger Song - Jefferies LLC, Research Division
Suranjit Mukherjee - BTIG, LLC, Research Division
Wei Ji Chang - Leerink Partners LLC, Research Division
Hello, and welcome, everyone, joining today's Second Quarter 2025 Kura Oncology, Inc. Financial Results Conference Call. [Operator Instructions] Please note this call is being recorded. [Operator Instructions] It is now my pleasure to turn the meeting over to Greg Mann, SVP of Investor Relations and Corporate Affairs. Please go ahead.
Greg Mann
Thank you, Brittany. Good afternoon, and welcome to Kura Oncology's Second Quarter 2025 Conference Call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer; Dr. Mollie Leoni, Chief Medical Officer; Brian Powl, Chief Commercial Officer; and Tom Doyle, Senior Vice President of Finance and Accounting.
Before I turn the call over to Dr. Wilson, we remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected results. Please refer to Kura's filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the